Valion Bio, Inc. Total Contract Liability
Valion Bio, Inc. (VBIO) had Total Contract Liability of $3.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-11-14
- 2025-09-30: Contract with Customer, Liability $3.00K.
- 2024-12-31: Contract with Customer, Liability $2.00K.
- 2022-12-31: Contract with Customer, Liability $2.00K.
- 2022-06-30: Contract with Customer, Liability $1.00K.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-14 |
| 2024-12-31 | $2.00K 10-Q · filed 2025-11-14 |
| 2022-12-31 | $2.00K 10-K · filed 2023-03-31 |
| 2022-06-30 | $1.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $3.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $3.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |